Cargando…
Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials
OBJECTIVES: This study investigated the clinical efficacy and safety of oral Janus kinase inhibitors (JAKis) in the treatment of hospitalized patients with COVID-19. METHODS: The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for releva...
Autores principales: | Tang, Hung-Jen, Weng, Teng-Song, Chen, Yu-Hung, Chao, Chien-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381941/ https://www.ncbi.nlm.nih.gov/pubmed/36031531 http://dx.doi.org/10.1016/j.jmii.2022.08.005 |
Ejemplares similares
-
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials
por: Chen, Ching-Yi, et al.
Publicado: (2021) -
Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022) -
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013) -
Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023) -
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
por: Tsai, Hou-Ren, et al.
Publicado: (2021)